Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis - 21/08/11
Arthur Kavanaugh, MD, University of California, San Diego, La Jolla, CA, United States; Gerald Krueger, MD, University of Utah Health Sciences Center, Salt Lake City, UT, United States; Songkai Yan, PhD, Centocor, Inc., Malvern, PA, United States; Christian Antoni, MD, Friedrich-Alexander University, Erlangen, Germany
Le texte complet de cet article est disponible en PDF. P2739 Dr. Kavanaugh has consulted and particpated in clinical research sponsored by Centocor, Amgen, and Abbott. Dr. Antoni is an investigator and consultant for infliximab at Centocor. Dr. Krueger is a consultant to Biogen, Genentech, and Centocor; on the sponsored speakers list for Amgen, Biogen, Genentech, and Centocor; neither Dr. Krueger nor his family own stock in these companies. Dr. Krueger has also participated in clinical trials for each of these companies. These studies were funded by a research grant from Centocor (IMPACT) or have been done by Centocor (IMPACT 2). |
Vol 52 - N° 3S
P. P181 - mars 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?